Search results
Results from the WOW.Com Content Network
Post-chemotherapy cognitive impairment (PCCI) (also known in the scientific community as " CRCIs or Chemotherapy-Related Cognitive Impairments " and in lay terms as chemotherapy-induced cognitive dysfunction or impairment, chemo brain, or chemo fog) describes the cognitive impairment that can result from chemotherapy treatment.
Lomustine is an alkylating chemotherapy drug that is indicated by the FDA for the treatment of patients with brain tumors (primary and metastatic), following any necessary surgery and radiation, as well as for treatment of progressive Hodgkin’s lymphoma. [8] Lomustine is approved for the treatment of brain tumors, breast cancer, lung cancer ...
One of the most common side effects of chemotherapy is “brain fog” — an experience where a ... while the other 29 started the exercise program after completing chemo. “Lifestyle changes, ...
Neurology. Chemotherapy-induced peripheral neuropathy (CIPN) is a nerve -damaging side effect of antineoplastic agents in the common cancer treatment, chemotherapy. [1] CIPN afflicts between 30% and 40% of patients undergoing chemotherapy. Antineoplastic agents in chemotherapy are designed to eliminate rapidly dividing cancer cells, but they ...
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) in a standard regimen. Chemotherapy may be given with a curative intent (which almost always involves combinations of drugs), or it may aim only to prolong life or ...
From the time of its inception, the use of adjuvant therapy has received scrutiny for its adverse effects on the quality of life of cancer patients. For example, because side effects of adjuvant chemotherapy can range from nausea to loss of fertility, physicians regularly practice caution when prescribing chemotherapy. [10]
Chemotherapy-induced peripheral neuropathy and thrombocytopenia are major side effects of bortezomib." [ 113 ] The addition of subcutaneous daratumumab to induction and consolidation therapy with bortezomib, lenalidomide, and dexamethasone, and to lenalidomide maintenance therapy, conferred improved progression-free survival among ...
Common side effects include vomiting, diarrhea, muscle pain, headache, and rash. Severe side effects may include fluid retention, gastrointestinal bleeding, bone marrow suppression, liver problems, and heart failure. Use during pregnancy may result in harm to the baby. Imatinib works by stopping the Bcr-Abl tyrosine-kinase.